Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05888987
Other study ID # PA23064
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 7, 2023
Est. completion date February 7, 2026

Study information

Verified date January 2024
Source CHU de Reims
Contact Alexandre DENOYER
Phone 03 26 78 78 88
Email adenoyer@chu-reims.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Microbial keratitis is a severe and often blindness-inducing pathology which represents today the first reason for long-term hospitalization (more than 5 days) in ophthalmology. Its diagnosis is clinical and leads to an immediate hospitalization in the presence of serious criteria (Mackie classification). The entire process of microbiological diagnosis requires several days before etiological confirmation and therefore delays the initiation of targeted therapy. Recently, new PCR systems allowing the detection of 18 to 27 pathogens in 75 minutes have been developed. Their use could thus be transposed to ophthalmology by adapting the microbiological diagnostic technique to samples currently taken by swabbing the cornea. The investigators will compare their diagnosis performance versus conventional methods on patients who suffered for a microbial keratitis with severity criteria.


Description:

46 patients enrolled for severe infectious keratitis will be recruited in the department of Ophthalmology, Robert Debré Hospital, Reims, France. The study will be composed by 2 groups. The first, also called "before group" will contain 23 patients who were anteriorly hospitalized for a severe infectious keratitis in our hospital unit. They received standard microbiological diagnosis methods: Direct microscopic examination with Gram stain, bacterial and fungal cultures, viral and amoebic polymerase chain reaction [PCR]). The second, also called "after group" will enroll patients who suffer for a severe infectious keratitis (prospective group). Each patient will benefit a complete ophthalmologic examination, corneal scrapping and swabbing for standard microbiological diagnosis methods along with another corneal swabbing sample for the use of two different FilmArray® PCR systems identified as "ME" for Meningitis-Encephalitis and "BCID" for Blood Culture Identification. The investigators hypothesize that the use of rapid multiplex PCR tests for the microbiological diagnosis of severe corneal infections could in the future prove to be more efficient than the current diagnostic strategy, on the one hand, by shortening the time to identify the pathogen and therefore to implement a targeted treatment, and on the other hand, by systematically searching for a large number of pathogens well beyond those targeted today. In addition, the benefits of this technique applied to ophthalmology could improve the long-term visual prognosis, reduce the length of hospitalization and therefore the diagnostic and management costs of these patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date February 7, 2026
Est. primary completion date July 7, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Over 18 years old - With social security affiliation - Willing to participate this study - Hospitalized in our department for severe infectious keratitis Non-inclusion criteria: - Any prior (48 hours) or concomitant treatment with local or systemic antibiotherapy at time of corneal scrapping and swabbing - Patient not covered by the French Health Insurance - Unable to give informed consent

Study Design


Intervention

Biological:
PCR multiplex by FilmArray
PCR multiplex by FilmArray system on corneal swabbing sample

Locations

Country Name City State
France Damien JOLLY Reims

Sponsors (1)

Lead Sponsor Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to modification of the first line antimicrobial treatment towards a treatment targeting the detected pathogen. At 2 weeks
Secondary Duration of hospitalization At 1 month
Secondary Best corrected visual acuity At 12 months
Secondary Modification of the initial antimicrobial treatment after detection of the etiological agent At 1 month
Secondary Descriptive analysis of pathogens responsible for severe infectious keratitis in Champagne-Ardenne At 1 month
Secondary • Costs of diagnostic methods (conventional and FilmArray) and management (cost of the average length of stay in ophthalmology at the Reims University Hospital for severe infectious keratitis) At 1 month
See also
  Status Clinical Trial Phase
Completed NCT04030403 - Investigation of the Microbiome of the Cornea in Microbial Keratitis
Completed NCT04213313 - Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis
Recruiting NCT02570321 - Cross-linking for Corneal Ulcers Treatment Trial Phase 4
Terminated NCT00912509 - Cross Linking for Treatment of Corneal Infection N/A
Completed NCT01831206 - Collagen Cross-linking in Infectious Keratitis Trial Phase 2
Completed NCT04383431 - Cross-linking as Treatment in Infectious Keratitis N/A
Not yet recruiting NCT03801590 - Crosslinking in Infectious Keratitis N/A
Recruiting NCT06364878 - Non-invasive Diagnostics of Microbial Keratitis
Completed NCT01739673 - Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis N/A
Completed NCT02819232 - Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs N/A